Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone
Open Access
- 28 June 2006
- journal article
- research article
- Published by Wiley in Diabetic Medicine
- Vol. 23 (7), 757-762
- https://doi.org/10.1111/j.1464-5491.2006.01914.x
Abstract
To compare the effects of nateglinide plus metformin with gliclazide plus metformin on glycaemic control in patients with Type 2 diabetes. Double-blind, double-dummy, parallel group, randomized, multicentre study over 24 weeks. Patients with inadequate glucose control on maximal doses of metformin were randomized to additionally receive nateglinide (n = 133) or gliclazide (n = 129). Changes from baseline in HbA1c, fasting plasma glucose (FPG) and mealtime glucose and insulin excursions were examined. HbA1c was significantly (P < 0.001) decreased from baseline in both treatment groups (mean changes: nateglinide −0.41%, gliclazide −0.57%), but with no significant difference between treatments. Proportions of patients achieving a reduction of HbA1c ≥ 0.5% or an end point HbA1c < 7% were also similar (nateglinide 58.1%, gliclazide 60.2%). Changes from baseline in FPG were similarly significant in both treatment groups (nateglinide −0.63, gliclazide −0.82 mmol/l). Reduction from baseline in maximum postprandial glucose excursion were significant in the nateglinide group only (nateglinide −0.71, gliclazide −0.10 mmol/l; P = 0.037 for difference). Postprandial insulin levels were significantly higher with nateglinide compared with gliclazide. The overall rate of hypoglycaemia events was similar in the nateglinide group compared with the gliclazide group.Keywords
This publication has 17 references indexed in Scilit:
- PRESERVE-βDiabetes Care, 2005
- Contributions of basal and post-prandial hyperglycaemia to micro- and macrovascular complications in people with type 2 diabetesCurrent Medical Research and Opinion, 2005
- Oral antihyperglycemic therapy for type 2 diabetes mellitusCMAJ : Canadian Medical Association Journal, 2005
- Hypoglycemic potential of nateglinide versus glyburide in patients with type 2 diabetes mellitusMetabolism, 2004
- Health and economic impact of combining metformin with nateglinide to achieve glycemic control: Comparison of the lifetime costs of complications in the U.KCost Effectiveness and Resource Allocation, 2004
- Nateglinide Improves Early Insulin Secretion and Controls Postprandial Glucose Excursions in a Prediabetic PopulationDiabetes Care, 2002
- Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patientsDiabetes, Obesity and Metabolism, 2002
- Global and societal implications of the diabetes epidemicNature, 2001
- Improved glycaemic control by addition of glimepiride to metformin monotherapy in Type 2 diabetic patientsDiabetic Medicine, 2001
- Glucose Tolerance and Cardiovascular MortalityArchives of Internal Medicine, 2001